Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma Subpopulations.
Fernández EC, Tomassoni L, Zhang X, Wang J, Obradovic A, Laise P, Griffin AT, Vlahos L, Minns HE, Morales DV, Simmons C, Gallitto M, Wei HJ, Martins TJ, Becker PS, Crawford JR, Tzaridis T, Wechsler-Reya RJ, Garvin J, Gartrell RD, Szalontay L, Zacharoulis S, Wu CC, Zhang Z, Califano A, Pavisic J. Fernández EC, et al. Among authors: tzaridis t. bioRxiv [Preprint]. 2024 Mar 17:2024.03.17.585370. doi: 10.1101/2024.03.17.585370. bioRxiv. 2024. PMID: 38559080 Free PMC article. Preprint.
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression.
Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A, Schlegel U, Steinbach JP, Seidel C, Goldbrunner R, Schäfer N, Wechsler-Reya RJ, Hallek M, Scheffler B, Glas M, Haeberle L, Herrlinger U, Coch C, Reiners KS, Hartmann G. Tzaridis T, et al. Int J Cancer. 2023 Jan 15;152(2):308-319. doi: 10.1002/ijc.34261. Epub 2022 Sep 17. Int J Cancer. 2023. PMID: 36054558 Free article.
A road map for the treatment of pediatric diffuse midline glioma.
Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M, Franson A, Galban S, Garcia Moure M, Garton H, Gowda P, Marques JG, Hawkins C, Heath A, Hulleman E, Ji S, Jones C, Kilburn L, Kline C, Koldobskiy MA, Lim D, Lowenstein PR, Lu QR, Lum J, Mack S, Magge S, Marini B, Martin D, Marupudi N, Messinger D, Mody R, Morgan M, Mota M, Muraszko K, Mueller S, Natarajan SK, Nazarian J, Niculcea M, Nuechterlein N, Okada H, Opipari V, Pai MP, Pal S, Peterson E, Phoenix T, Prensner JR, Pun M, Raju GP, Reitman ZJ, Resnick A, Rogawski D, Saratsis A, Sbergio SG, Souweidane M, Stafford JM, Tzaridis T, Venkataraman S, Vittorio O, Wadden J, Wahl D, Wechsler-Reya RJ, Yadav VN, Zhang X, Zhang Q, Venneti S. Koschmann C, et al. Among authors: tzaridis t. Cancer Cell. 2024 Jan 8;42(1):1-5. doi: 10.1016/j.ccell.2023.11.002. Epub 2023 Nov 30. Cancer Cell. 2024. PMID: 38039965
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: tzaridis t. J Neurooncol. 2023 Nov;165(2):387. doi: 10.1007/s11060-023-04488-z. J Neurooncol. 2023. PMID: 37921974 Free PMC article. No abstract available.
Assessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles.
Brahmer A, Geiß C, Lygeraki A, Neuberger E, Tzaridis T, Nguyen TT, Luessi F, Régnier-Vigouroux A, Hartmann G, Simon P, Endres K, Bittner S, Reiners KS, Krämer-Albers EM. Brahmer A, et al. Among authors: tzaridis t. Cell Commun Signal. 2023 Oct 6;21(1):276. doi: 10.1186/s12964-023-01308-9. Cell Commun Signal. 2023. PMID: 37803478 Free PMC article.
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
Weller J, Zeyen T, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Hau P, Seidel C, Goldbrunner R, Tabatabai G, Vatter H, Tzaridis T, Schneider M, Herrlinger U. Weller J, et al. Among authors: tzaridis t. J Neurooncol. 2023 Sep;164(3):749-755. doi: 10.1007/s11060-023-04470-9. Epub 2023 Oct 3. J Neurooncol. 2023. PMID: 37787906 Free PMC article.
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: tzaridis t. J Neurooncol. 2023 Sep;164(3):607-616. doi: 10.1007/s11060-023-04444-x. Epub 2023 Sep 20. J Neurooncol. 2023. PMID: 37728779 Free PMC article.
Distress in Neuro-Oncology Patients and Its Implications for Communication.
Roos C, Weller J, Landwehr C, Sciermoch A, Duffy C, Kohlmann K, Schaub C, Tzaridis T, Schneider M, Schuss P, Herrlinger U, Schäfer N. Roos C, et al. Among authors: tzaridis t. J Adv Pract Oncol. 2023 May;14(4):292-299. doi: 10.6004/jadpro.2023.14.4.3. Epub 2023 May 1. J Adv Pract Oncol. 2023. PMID: 37313277 Free PMC article.
35 results